Misplaced Pages

Pateclizumab: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 19:59, 30 October 2011 editThe chemistds (talk | contribs)Extended confirmed users5,761 edits No ChemSpider ID for this record← Previous edit Revision as of 09:29, 31 October 2011 edit undoBeetstra (talk | contribs)Edit filter managers, Administrators172,084 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number').Next edit →
Line 28: Line 28:


<!--Identifiers--> <!--Identifiers-->
| CAS_number = 1202526-59-7 | CAS_number = <!-- blanked - oldvalue: 1202526-59-7 -->
| ATC_prefix = none | ATC_prefix = none
| ATC_suffix = | ATC_suffix =

Revision as of 09:29, 31 October 2011

Pharmaceutical compound
Pateclizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
Targetlymphotoxin alpha
Clinical data
ATC code
  • none
Identifiers
ChemSpider

Pateclizumab is an immunomodulator. It binds to lymphotoxin alpha.

References

  1. World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
Monoclonal antibodies for the immune system
Immune system
Human
Mouse
Chimeric
Humanized

Immune activation: Dostarlimab
Other: Ibalizumab

Chimeric + humanized
Interleukin
Human
Humanized
Veterinary
Inflammatory lesions
Mouse


Stub icon

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Pateclizumab: Difference between revisions Add topic